Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R7XD
|
|||
| Former ID |
DNCL002807
|
|||
| Drug Name |
GSK1325756
|
|||
| Synonyms |
Danirixin; 954126-98-8; GSK1325756; UNII-R318PGH5VP; GSK-1325756B; R318PGH5VP; GSK1325756B; Danirixin [USAN:INN]; GSK-1325756; GSK 1325756; Danirixin (USAN/INN); Danirixin(GSK1325756); GTPL8500; SCHEMBL1198688; CHEMBL3039531; MolPort-044-561-791; EX-A1178; ZINC95627831; AKOS030527036; DB11922; CS-5465; 1-(4-Chloro-2-hydroxy-3-(((3S)-piperidine-3-sulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea; HY-19768; D10387; (S)-1-(4-chloro-2-hydroxy-3-(piperidin-3-ylsulfonyl)phenyl)-3-(3-fluoro-2-methylphenyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [1], [2] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21ClFN3O4S
|
|||
| Canonical SMILES |
CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)C3CCCNC3)O
|
|||
| InChI |
1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
|
|||
| InChIKey |
NGYNBSHYFOFVLS-LBPRGKRZSA-N
|
|||
| CAS Number |
CAS 954126-98-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Modulator | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Endocytosis | ||||
| Epithelial cell signaling in Helicobacter pylori infection | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8500). | |||
| REF 2 | ClinicalTrials.gov (NCT02469298) Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza. | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.